Zydus gets USFDA approval for Roflumilast Tablets, 250 mcg
Roflumilast reduces inflammation in the lungs that leads to chronic obstructive pulmonary disease (COPD)
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Roflumilast tablets
Zydus gets 180 days’ shared exclusivity for Roflumilast tablets
Zydus’ Roflumilast tablets are indicated as a treatment to reduce the risk of Chronic Obstructive Pulmonary Disease (COPD)…
Strides Shasun receives USFDA tentative approval for Roflumilast tablets
The product can be launched earliest by January 2020
Strides Shasun has announced that it has received tentative approval from the…